Short-term effects of chemotherapy-surgery-chemotherapy regimen on clinically inoperable advanced ovarian cancer

Chinese Medical Journal

Volumn 111, Issue 8, 1998, Pages 722-725

  Feng, Yuzeng ^a   Sun, Tingwei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOMYCIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; OVARY CANCER; TREATMENT INDICATION; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 7344252998     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Shimizu Y, Hasumi K. Treatment of stage 3 and stage 4 ovarian cancer: is neoadjuvant chemotherapy effective? Acta Obstet Gynecol Jpn 1993; 45:1007.
2. Lam JT, Green JA. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage 3 and stage 4 ovarian cancer. Clin Oncol (R Coll Radiol) 1993; 5:198.
3. Jacob JH, Gershenson DM, Morris M, et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991; 42:146.
4. Schwarte PE, Chambers JT, Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 1994; 53:33.